Merck KGaA’s (MRK) “Buy” Rating Reaffirmed at DZ Bank

Merck KGaA (FRA:MRK)‘s stock had its “buy” rating reissued by equities research analysts at DZ Bank in a report released on Wednesday, Borsen Zeitung reports.

A number of other research analysts also recently weighed in on the stock. Nord/LB set a €94.00 ($109.30) price objective on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Friday, August 9th. Morgan Stanley set a €96.00 ($111.63) price objective on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Tuesday, June 18th. Credit Suisse Group set a €110.00 ($127.91) price objective on shares of Merck KGaA and gave the company a “buy” rating in a research report on Thursday, August 8th. Warburg Research set a €103.00 ($119.77) price objective on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Tuesday, July 30th. Finally, JPMorgan Chase & Co. set a €100.00 ($116.28) price objective on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of €100.67 ($117.05).

Shares of FRA:MRK traded down €1.60 ($1.86) during trading on Wednesday, reaching €93.52 ($108.74). 278,984 shares of the stock traded hands. The firm’s 50-day moving average price is €93.68. Merck KGaA has a 52-week low of €76.60 ($89.07) and a 52-week high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Article: Is a Roth IRA right for you?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.